Overview

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

Status:
Recruiting

Trial end date:
2024-05-30

Target enrollment:

Participant gender:

Summary

An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for advanced melanoma with BRAF V600 mutation

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Henlius Biotech